ACULYS is tackling the social issues in neurology head-on
At ACULYS, our innovative solutions are transforming the field of neurology in Japan—improving the lives of patients and families affected by these complex neuroscience diseases.
News
アキュリスファーマのニュースリリースは、当社の企業活動を報道関係者の皆さまへ情報提供することを目的に発信しております。医薬品・開発品の情報を含む場合がありますが、広告・プロモーションや医学的なアドバイス等を目的とするものではありません。
ACULYS News Releases are issued to provide press journalists with the information related to our company. In some instances, information on products or drug candidates under development may be included, but it is not intended for promotional or advertising purposes, or as medical advice, etc.
- Aculys Pharma Delivers Positive Results in Domestic Phase III Clinical Trial of Pitolisant for Narcolepsy Patients
- Aculys Pharma Files New Drug Application for Diazepam Nasal Spray in Japan: An Antiepileptic Drug for the Treatment of Epileptic Seizures
- Aculys Pharma Completes Patient Enrollment for Phase 3 Clinical Trial on Pitolisant in Patients with Narcolepsy
- Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO
- Aculys Pharma receives orphan drug designation for a diazepam nasal spray: an antiepileptic drug for epileptic seizures
Features
Singular focus on neurology
We are a clinical stage biopharmaceutical company focused on neuroscience diseases, where there is a high unmet medical need.
Accelerating delivery for
innovative treatments and medical means
At ACULYS, we're breaking down barriers to bring innovative neurological treatments to Japan, faster. By focusing on medicines already approved in other countries, we're cutting through Japan’s drug lag and delivering life-changing therapies to patients and families who need them.
Outstanding knowledge and dedication
Our experienced team members, who have contributed to the growth of major global pharmaceutical companies, are combining their knowledge and expertise to achieve our mission of addressing the stigmas and social issues related to neuroscience diseases.
Origin of company name
ACULYS serves the unmet needs of patients in Japan through
improved access to innovative neurological treatments.